


In the Claims

Please amend Claims 15-17, 24, 30-32, 71, 80, 94 and 98. Cancel claims 1-14, 33-70 and 101-107. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - vii).

Please add new claims 108-160.

15. (Amended) A compound of Formula III,



or a physiologically acceptable salt thereof, wherein:

R₈ is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;

R₉ is a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R₁₀ is alkyl substituted with NR₁₃R₁₄, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;

R₁₁ is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenone, or a substituted or unsubstituted cycloalkylalkyl;


R₁₂ is H; and

R_{13} and R_{14} together with the nitrogen to which they are attached are a heterocycloalkyl.

- A₁
16. (Amended) The compound of Claim 15, wherein R_8 is substituted or unsubstituted phenyl, phenyl- C_1 - C_4 -alkyl, diphenyl- C_1 - C_4 -alkyl, linear C_1 - C_{12} -alkyl, branched C_1 - C_{12} -alkyl, cyclic C_3 - C_{12} -alkyl, or dicycloalkyl- C_1 - C_4 -alkyl.
17. (Amended) The compound of Claim 16, wherein R_8 is phenyl, phenyl- C_1 - C_4 -alkyl, or diphenyl- C_1 - C_4 -alkyl wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of C_1 - C_4 -alkoxy, C_1 - C_4 -alkyl and cyano.
-


- A₂
24. (Amended) The compound of Claim 15, wherein R_{10} is substituted or unsubstituted phenyl, unsubstituted heteroaraalkyl group, unsubstituted heterocycloalkylalkyl group, or an alkyl substituted with $-NR_{13}R_{14}$.
-

30. (Amended) A composition comprising an enantiomeric mixture of a compound represented by the following structural formula:




or a physiologically acceptable salt thereof.

31. (Amended) A compound which has a positive specific rotation, wherein the compound is represented by the following structural formula:




or a physiologically acceptable salt thereof.

32. (Amended) A compound which has a negative specific rotation, wherein the compound is represented by the following structural formula:



or a physiologically acceptable salt thereof.

71. (Amended) A method of treating a TNF- α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula III,



or a physiologically acceptable salt thereof, wherein:

R_8 and R_{12} are each, independently, -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;

R_9 is -H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is alkyl substituted with $NR_{13}R_{14}$, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;

R_{11} is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl; and


R_{13} and R_{14} are independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl or unsubstituted aralkyl or R_{13} and R_{14} together with the nitrogen to which they are attached are a heterocycloalkyl.

80. (Amended) The method of Claim 71, wherein R_{10} is substituted or unsubstituted phenyl, unsubstituted heteroaralkyl group, unsubstituted heterocycloalkylalkyl group, or an alkyl substituted with $-NR_{13}R_{14}$.

94. (Amended) The method of Claim 93, wherein the TNF- α mediated condition is selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, acute transverse myelitis, lesions of the corticospinal system, disorders of the basal ganglia or cerebellar disorders, hyperkinetic movement disorders such as Huntington's Chorea and senile chorea, drug-induced movement disorders, hypokinetic movement disorders, progressive supranucleo palsy, astructural lesions of the cerebellum, spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple systems degenerations,

A6 Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, mitochondrial multisystem disorder, acute transverse myelitis, neurogenic muscular atrophies, Alzheimer's disease, Down's Syndrome in middle age, Diffuse Lewy body disease, Senile Dementia of Lewy body type, Wernicke-Korsakoff syndrome, chronic alcoholism, Creutzfeldt-Jakob disease, Subacute sclerosing panencephalitis, Hallerorden-Spatz disease, and Dementia pugilistica.


98. (Amended) A method of treating a TNF- α mediated condition in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:



or a physiologically acceptable salt thereof.

Please add new Claims 108-160.

108. (New) The method according to Claim ~~71~~ wherein the TNF- α mediated condition is graft rejection.
109. (New) A compound according to Formula III:



A8

or a physiologically acceptable salt thereof, wherein;

R_8 is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl or substituted or unsubstituted heteroaralkyl;

R_9 is a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is an alkyl substituted with $NR_{13}R_{14}$ or a substituted or unsubstituted heteroaralkyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted benzophenone or a substituted or unsubstituted cycloalkyl;

R_{12} is H; and

R_{13} and R_{14} together with the nitrogen to which they are attached are a heterocycloalkyl.


110. (New) A compound according to Claim 109 wherein R_{10} is an unsubstituted heteroaralkyl.

111. (New) A compound according to Claim 110 wherein said heteroaraalkyl is C₁₋₆ alkyl pyridyl, C₁₋₆ alkyl pyrimidyl, C₁₋₆ alkyl quinolyl, C₁₋₆ alkyl isoquinolyl, C₁₋₆ alkyl pyrrolyl, C₁₋₆ alkyl quinoxalyl, C₁₋₆ alkyl imidazolyl, C₁₋₆ alkyl oxazolyl, C₁₋₆ alkyl isoxazolyl, C₁₋₆ alkyl pyrazolyl, C₁₋₆ alkyl thienyl, C₁₋₆ alkyl furanyl, C₁₋₆ alkyl pyrazolyl, C₁₋₆ alkyl thiadiazolyl, C₁₋₆ alkyl oxadiazolyl, C₁₋₆ alkyl indazolyl, C₁₋₆ alkyl thiazolyl, C₁₋₆ alkyl isothiazolyl, C₁₋₆ alkyl tetrazolyl, C₁₋₆ alkyl benzo (b) thienyl, C₁₋₆ alkyl benzimidazolyl, C₁₋₆ alkyl benzoxazolyl, C₁₋₆ alkyl benzothiazolyl, C₁₋₆ alkyl benzothiadiazolyl, C₁₋₆ alkyl benzoxadiazolyl, C₁₋₆ alkyl indolyl, C₁₋₆ alkyl tetrahydroindolyl, C₁₋₆ alkyl azaindolyl, C₁₋₆ alkyl indazolyl, C₁₋₆ alkyl quinolinyl, C₁₋₆ alkyl imidazopyridyl, C₁₋₆ alkyl puryl, C₁₋₆ alkyl pyrrolo[2,3-d]pyrimidyl, C₁₋₆ alkyl pyrazolo[3,4-d]pyrimidyl.
112. (New) A compound according to Claim 111 wherein R₉ is unsubstituted or substituted aryl.
113. (New) A compound according to Claim 112 wherein R₉ is substituted or unsubstituted phenyl.
114. (New) A compound according to Claim 110 wherein R₁₁ is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C₁-C₄-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C₁-C₄-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C₁-C₄-alkyl, naphthyl, naphthyl-C₁-C₄-alkyl, diphenyl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl-C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl-C₁-C₄-alkyl, fluorenyl, pyrrolyl, N-methylpyrrolyl, or pyridyl.
115. (New) A compound according to Claim 114 wherein R₁₁ is unsubstituted or substituted benzophenonyl.
116. (New) A compound according to Claim 109 wherein R₈ is phenyl, phenyl-C₁-C₄-alkyl, or diphenyl-C₁-C₄-alkyl wherein the phenyl group or phenyl groups optionally bear

one or more substituents independently selected from the group consisting of C₁-C₄-alkoxy, C₁-C₄-alkyl and cyano.

117. (New) The compound of Claim 116, wherein R₈ is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

118. (New) A compound according to formula:



or a physiologically acceptable salt thereof, wherein;

R₈ is H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl or substituted or unsubstituted heteroaralkyl;

R₉ is a substituted or unsubstituted phenyl;

R₁₀ is a C₁-C₆ alkyl imidazolyl;

R₁₁ is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted benzophenone or a substituted or unsubstituted cycloalkyl; and

R₁₂ is H.

119. (New) A compound according to Claim 118 wherein R₈ is phenyl, phenyl-C₁-C₄-alkyl, or diphenyl-C₁-C₄-alkyl wherein the phenyl group or phenyl groups bear one or more


substituents independently selected from the group consisting of C₁-C₄-alkoxy, C₁-C₄-alkyl and cyano.

120. (New) The compound of Claim 119, wherein R₈ is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

121. (New) A compound according to Claim 118 wherein R₁₁ is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C₁-C₄-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C₁-C₄-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C₁-C₄-alkyl, naphthyl, naphthyl-C₁-C₄-alkyl, diphenyl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl-C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl-C₁-C₄-alkyl, fluorenyl, pyrrololyl, N-methylpyrrololyl, or pyridyl.

122. (New) A compound according to Claim 121 wherein R₁₁ is substituted or unsubstituted benzophenonyl.

123. (New) A method of treating a TNF- α mediated condition in a patient comprising administering to a patient a therapeutically effective amount of



or a physiologically acceptable salt thereof, wherein

R_8 and R_{12} are each independently H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl or substituted or unsubstituted heteroaralkyl;

R_9 is H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is an alkyl substituted with $NR_{13}R_{14}$, or a substituted or unsubstituted heteroaralkyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted benzophenone or a substituted or unsubstituted cycloalkyl; and

R_{13} and R_{14} are each, independently, -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted aralkyl; or

R_{13} and R_{14} together with the nitrogen to which they are attached are a heterocycloalkyl.

124. (New) The method according to Claim 123 wherein R_{10} is an unsubstituted heteroaralkyl.
125. (New) The method according to Claim 124 wherein R_{12} is hydrogen.
126. (New) The method according to Claim 125 wherein said heteroaralkyl is C_{1-6} alkyl pyridyl, C_{1-6} alkyl pyrimidyl, C_{1-6} alkyl quinolyl, C_{1-6} alkyl isoquinolyl, C_{1-6} alkyl pyrrolyl, C_{1-6} alkyl quinoxalyl, C_{1-6} alkyl imidazolyl, C_{1-6} alkyl oxazolyl, C_{1-6} alkyl isoxazolyl, C_{1-6} alkyl pyrazolyl, C_{1-6} alkyl thienyl, C_{1-6} alkyl furanyl, C_{1-6} alkyl pyrazolyl, C_{1-6} alkyl thiadiazolyl, C_{1-6} alkyl oxadiazolyl, C_{1-6} alkyl indazolyl, C_{1-6} alkyl thiazolyl, C_{1-6} alkyl isothiazolyl, C_{1-6} alkyl tetrazolyl, C_{1-6} alkyl benzo (b) thienyl, C_{1-6} alkyl benzimidazolyl, C_{1-6} alkyl benzoxazolyl, C_{1-6} alkyl benzothiazolyl, C_{1-6} alkyl benzothiadiazolyl, C_{1-6} alkyl benzoxadiazolyl, C_{1-6} alkyl


indolyl, C₁₋₆ alkyl tetrahydroindolyl, C₁₋₆ alkyl azaindolyl, C₁₋₆ alkyl indazolyl, C₁₋₆ alkyl quinolinyl, C₁₋₆ alkyl imidazopyridyl, C₁₋₆ alkyl puryl, C₁₋₆ alkyl pyrrolo[2,3-d]pyrimidyl, or C₁₋₆ alkyl pyrazolo[3,4-d]pyrimidyl.

127. (New) The method according to Claim 126 wherein R₉ is unsubstituted or substituted aryl.
128. (New) The method according to Claim 127 wherein R₉ is substituted or unsubstituted phenyl.
- 46 129. (New) The method according to Claim 123 wherein R₁₁ is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C₁-C₄-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C₁-C₄-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C₁-C₄-alkyl, naphthyl, naphthyl-C₁-C₄-alkyl, diphenyl-C₁-C₄-alkyl, C₅-C₈-cycloalkyl-C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl-C₁-C₄-alkyl, fluorenyl, pyrrolyl, N-methylpyrrolyl, or pyridyl.
130. (New) The method according to Claim 129 wherein R₁₁ is unsubstituted or substituted benzophenonyl.
131. (New) The method according to Claim 123 wherein R₈ is phenyl, phenyl-C₁-C₄-alkyl, or diphenyl-C₁-C₄-alkyl wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of C₁-C₄-alkoxy, C₁-C₄-alkyl and cyano.
132. (New) The method of Claim 131, wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of methoxy, methyl, ethyl and cyano.

133. (New) The method of Claim 131, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.
134. (New) The method of Claim 123, wherein the TNF- α mediated condition is selected from the group consisting of acute and chronic immune and autoimmune pathologies.
135. (New) The method of Claim 134, wherein the TNF- α mediated condition is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, thyroidosis, graft versus host disease, scleroderma, diabetes mellitus and Graves' disease.
136. (New) The method of Claim 123, wherein the TNF- α mediated condition is an infection.
137. (New) The method of Claim 136, wherein the TNF- α mediated condition is selected from the group consisting of sepsis syndrome, cachexia, circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic, bacterial, viral and fungal infectious diseases.
-
138. (New) The method according to Claim 123 wherein the TNF- α mediated condition is graft rejection.
-
139. (New) The method of Claim 123, wherein the TNF- α mediated condition is an inflammatory disease.

140. (New) The method of Claim 139, wherein the TNF- α mediated condition is selected from the group consisting of chronic inflammatory pathologies and vascular inflammatory pathologies.
141. (New) The method of Claim 140, wherein the TNF- α mediated condition is selected from the group consisting of sarcoidosis, chronic inflammatory bowel disease, ulcerative colitis, Crohn's disease, disseminated intravascular coagulation, atherosclerosis, and Kawasaki's pathology.
- Ag 142. (New) The method of Claim 123, wherein the TNF- α mediated condition is a neurodegenerative disease.
143. (New) The method of Claim 142, wherein the TNF- α mediated condition is selected from the group consisting of amyotrophic lateral sclerosis multiple sclerosis, acute transverse myelitis, lesions of the corticospinal system, disorders of the basal ganglia or cerebellar disorders, hyperkinetic movement disorders such as Huntington's Chorea and senile chorea, drug-induced movement disorders, hypokinetic movement disorders, progressive supranucleo palsy, astructural lesions of the cerebellum, spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple systems degenerations, Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, mitochondrial multisystem disorder, acute transverse myelitis, neurogenic muscular atrophies, Alzheimer's disease, Down's Syndrome in middle age, Diffuse Lewy body disease, Senile Dementia of Lewy body type, Wernicke-Korsakoff syndrome, chronic alcoholism, Creutzfeldt-Jakob disease, Subacute sclerosing panencephalitis, Hallerorden-Spatz disease, and Dementia pugilistica.
144. (New) The method of Claim 123, wherein the TNF- α mediated condition is cancer.

145. (New) The method of Claim 144, wherein the TNF- α mediated condition is selected from the group consisting of TNF- α secreting tumors, leukemias, and lymphomas.
146. (New) The method of Claim 123, wherein the TNF- α mediated condition is alcohol-induced hepatitis.
147. (New) A method of treating a TNF- α mediated condition in a patient comprising administering to a patient a therapeutically effective amount of formula:



or a physiologically acceptable salt thereof, wherein;

R_8 is H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl or substituted or unsubstituted heteroaralkyl;

R_9 is a substituted or unsubstituted phenyl;

R_{10} is a C_1 - C_6 alkyl imidazolyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted benzophenone or a substituted or unsubstituted cycloalkyl; and

R_{12} is hydrogen.

148. (New) The method according to Claim 147 wherein R_8 is hydrogen and the other is phenyl, phenyl- C_1 - C_4 -alkyl, or diphenyl- C_1 - C_4 -alkyl wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of C_1 - C_4 -alkoxy, C_1 - C_4 -alkyl and cyano.

149. (New) The method according Claim 148, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.
150. (New) The method according to Claim 147 wherein R_{11} is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl- C_1 - C_4 -alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl- C_1 - C_4 -alkyl, pyridylcarbonylphenyl, phenylcarbonyl- C_1 - C_4 -alkyl, naphthyl, naphthyl- C_1 - C_4 -alkyl, diphenyl- C_1 - C_4 -alkyl, C_5 - C_8 -cycloalkyl- C_1 - C_4 -alkyl, C_1 - C_4 -alkylcarbonyl- C_1 - C_4 -alkyl, fluorenyl, pyrrolyl, N-methylpyrrolyl, or pyridyl.
151. (New) The method according to Claim 150 wherein R_{11} is substituted or unsubstituted benzophenonyl.
152. (New) The method of Claim 147, wherein the TNF- α mediated condition is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, thyroidosis, graft versus host disease, scleroderma, diabetes mellitus and Graves' disease.
153. (New) The method of Claim 147, wherein the TNF- α mediated condition is selected from the group consisting of sepsis syndrome, cachexia, circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic, bacterial, viral and fungal infectious diseases.

154 (New) The method according to Claim 147 wherein the TNF- α mediated condition is graft rejection.

155. (New) The method of Claim 147, wherein the TNF- α mediated condition is an inflammatory disease.
156. (New) The method of Claim 147, wherein the TNF- α mediated condition is selected from the group consisting of sarcoidosis, chronic inflammatory bowel disease, ulcerative colitis, Crohn's disease, disseminated intravascular coagulation, atherosclerosis, and Kawasaki's pathology.
157. (New) The method of Claim 147, wherein the TNF- α mediated condition is selected from the group consisting of amyotrophic lateral sclerosis multiple sclerosis, acute transverse myelitis, lesions of the corticospinal system, disorders of the basal ganglia or cerebellar disorders, hyperkinetic movement disorders such as Huntington's Chorea and senile chorea, drug-induced movement disorders, hypokinetic movement disorders, progressive supranucleo palsy, astructural lesions of the cerebellum, spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple systems degenerations, Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, mitochondrial multisystem disorder, acute transverse myelitis, neurogenic muscular atrophies, Alzheimer's disease, Down's Syndrome in middle age, Diffuse Lewy body disease, Senile Dementia of Lewy body type, Wernicke-Korsakoff syndrome, chronic alcoholism, Creutzfeldt-Jakob disease, Subacute sclerosing panencephalitis, Hallerorden-Spatz disease, and Dementia pugilistica.
158. (New) The method of Claim 147, wherein the TNF- α mediated condition is cancer.
159. (New) The method of Claim 158, wherein the TNF- α mediated condition is selected from the group consisting of TNF- α secreting tumors, leukemias, and lymphomas.

A8